GSK Announces Positive Phase III Trial Results for Nucala in COPD Patients
GSK has announced promising headline results from its Phase III clinical trial, MATINEE, which evaluated the efficacy of Nucala (mepolizumab)
Read moreGSK has announced promising headline results from its Phase III clinical trial, MATINEE, which evaluated the efficacy of Nucala (mepolizumab)
Read moreThe GERBU Adjuvant MTM is developed specifically for monoclonal antibody production and offers a high yield of IgG and fused
Read moreJohnson & Johnson (NYSE: JNJ) has announced promising outcomes from its Phase 3 Vivacity-MG study, evaluating Nipocalimab in patients with
Read moreIn a significant milestone for the pharmaceutical industry, Merck KGaA has established itself as the pioneer Contract Testing, Development, and
Read moreThe Biosimilar Tyruko® has been approved for all indications of reference medicine, as the first and only biosimilar to treat
Read moreThe MANDARA Phase III trial marks the first head-to-head comparison of biologics in treating eosinophilic granulomatosis with polyangiitis (EGPA), putting
Read moreThe partnership with Samsung Bioepis Grants Novartis’ generic-drugs unit Sandoz exclusive commercialization rights for biosimilar SB17 Ustekinumab in Europe and
Read moreThe new Anti-mouse CD45 Antibody from HistoSure is specifically developed for superior results in IHC-P (FFPE) applications. Anti-Mouse CD45 Antibody
Read moreInflaRx N.V., a biopharmaceutical company in the clinical stage of developing anti-inflammatory therapeutics that target the complement system, has announced
Read moreGERBU’s Ready-to-use Immunoadjuvants are Economical and Animal Friendly A GERBU Biotechnik .pdf Brochure The unique GERBU Adjuvant PluS, Adjuvant S,
Read more